Cosmo Sets April General Meeting with Name Change and Payout on Agenda

COSMO Pharmaceuticals N.V. ( (CH:COPN) ) has issued an update.

Cosmo Pharmaceuticals N.V. has convened its ordinary General Meeting for 10 April 2026 in Amsterdam, where shareholders will review the 2025 financial year and ESG achievements and decide on profit appropriation. The agenda also includes a proposed EUR 2.10 per share distribution from freely available reserves, discharge of the board from liability, approval of the remuneration policy and reappointment of board members for one-year terms.

Shareholders will vote on amending the articles of association to change the company name to Cosmo N.V. and on several authorizations for the board to issue ordinary and preference shares or grant subscription rights. These measures, alongside updated governance and capital authorization proposals, could influence Cosmo’s capital structure, branding and governance framework, with implications for its strategic flexibility and investor returns.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF130.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

More about COSMO Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V. is a life-science company focused on MedTech AI, dermatology, gastrointestinal diseases and contract development and manufacturing services. Founded in 1997 and headquartered in Dublin with offices in the U.S. and Italy, it develops and manufactures advanced medical solutions used by global pharma and MedTech partners.

Average Trading Volume: 61,449

Technical Sentiment Signal: Buy

Current Market Cap: CHF1.58B

See more insights into COPN stock on TipRanks’ Stock Analysis page.